Louise Goodwin
Papers
5
Total Citations
464
H-Index
5
About
Louise Goodwin is a leading urologic surgeon and clinical researcher whose work is fundamentally reshaping the surgical management of bladder cancer. Her primary research focus lies in the comparative effectiveness of robot-assisted radical cystectomy (RARC) versus traditional open surgery, with a specific emphasis on patient recovery, morbidity, and healthcare economics. Goodwin’s landmark contribution is the iROC trial, a pivotal randomized controlled trial that directly compared robot-assisted radical cystectomy with intracorporeal urinary diversion to the open approach. The trial’s primary results, published in 2022 and garnering over 320 citations, demonstrated that robotic surgery significantly reduces 90-day morbidity and improves recovery without compromising oncologic outcomes. This work has provided the highest-level evidence supporting the adoption of minimally invasive techniques for this complex procedure. Beyond clinical outcomes, Goodwin has also led critical cost-effectiveness analyses, showing that robotic cystectomy offers good value for healthcare systems. Her innovative use of wearable devices and cardiopulmonary exercise testing to predict postoperative complications further highlights her commitment to personalizing surgical care. Through her rigorous, high-impact research, Louise Goodwin is directly influencing surgical standards and improving the quality of life for patients with bladder cancer worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5